BIOMAT Database Logo BIOMAT Database Logo

Local and systemic response of mice to interferon-alpha 1-transfected Friend leukemia cells. 1995

L Gabriele, and T Kaido, and D Woodrow, and J Moss, and M Ferrantini, and E Proletti, and L Santodonato, and C Rozera, and C Maury, and F Belardelli
Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy.

DBA/2 mice were injected subcutaneously with an interferon (IFN)-alpha/beta-resistant line of Friend erythroleukemia cells (FLC) transfected with the mouse IFN-alpha 1 gene. These tumor cells produced IFN constitutively, and mice had persistently high levels of IFN in the circulation. We examined the IFN-induced host mechanisms responsible for the local inhibition of growth of these IFN-alpha-transfected FLC and some of the unusual systemic effects of constant interferonemia such as extramedullary hematopoiesis in the liver, an increase in myeloid cells in the spleen, and persistently elevated splenic natural killer (NK) cell activity. In addition, both DBA/2 +/bg and beige mice developed a rapid and specific resistance to intravenous challenge with parental FLC. In previous experiments DBA/2 beige mice could not be protected by exogenous IFN-alpha/beta. The differences in the response of mice to the constitutive production of IFN-alpha by IFN-alpha-transfected tumor cells and their response to exogenous IFN is discussed in terms of the effects of IFN on the host and of antitumor therapy.

UI MeSH Term Description Entries
D007121 Immunocompetence The ability of lymphoid cells to mount a humoral or cellular immune response when challenged by antigen. Competence, Immunologic,Immunologic Competence,Immunological Competence,Competence, Immunological
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004915 Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. Di Guglielmo's Disease,Erythremic Myelosis,Erythroblastic Leukemia, Acute,Erythroleukemia,Leukemia, Myeloid, Acute, M6,Myeloid Leukemia, Acute, M6,Di Guglielmo Disease,Acute Erythroblastic Leukemia,Acute Erythroblastic Leukemias,Di Guglielmos Disease,Disease, Di Guglielmo,Disease, Di Guglielmo's,Erythremic Myeloses,Erythroblastic Leukemias, Acute,Erythroleukemias,Leukemia, Acute Erythroblastic,Leukemias, Acute Erythroblastic,Myeloses, Erythremic,Myelosis, Erythremic

Related Publications

L Gabriele, and T Kaido, and D Woodrow, and J Moss, and M Ferrantini, and E Proletti, and L Santodonato, and C Rozera, and C Maury, and F Belardelli
Interferon and Friend leukemia cells in culture.
January 1977, Texas reports on biology and medicine,
L Gabriele, and T Kaido, and D Woodrow, and J Moss, and M Ferrantini, and E Proletti, and L Santodonato, and C Rozera, and C Maury, and F Belardelli
Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I.
December 1982, International journal of cancer,
L Gabriele, and T Kaido, and D Woodrow, and J Moss, and M Ferrantini, and E Proletti, and L Santodonato, and C Rozera, and C Maury, and F Belardelli
Response of severe systemic mastocytosis to interferon alpha.
March 1998, The British journal of dermatology,
L Gabriele, and T Kaido, and D Woodrow, and J Moss, and M Ferrantini, and E Proletti, and L Santodonato, and C Rozera, and C Maury, and F Belardelli
The effect of interferon preparations on Friend leukemia of mice.
January 1968, Bibliotheca haematologica,
L Gabriele, and T Kaido, and D Woodrow, and J Moss, and M Ferrantini, and E Proletti, and L Santodonato, and C Rozera, and C Maury, and F Belardelli
Interferon and murine leukemia. I. Inhibitory effect of interferon preparations on development of friend leukemia in mice.
January 1967, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
L Gabriele, and T Kaido, and D Woodrow, and J Moss, and M Ferrantini, and E Proletti, and L Santodonato, and C Rozera, and C Maury, and F Belardelli
Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms.
December 1982, International journal of cancer,
L Gabriele, and T Kaido, and D Woodrow, and J Moss, and M Ferrantini, and E Proletti, and L Santodonato, and C Rozera, and C Maury, and F Belardelli
Friend murine leukemia virus and spleen focus-forming virus expression in highly malignant interferon-sensitive and interferon-resistant Friend leukemia cells.
April 1986, Virology,
L Gabriele, and T Kaido, and D Woodrow, and J Moss, and M Ferrantini, and E Proletti, and L Santodonato, and C Rozera, and C Maury, and F Belardelli
Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells.
January 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
L Gabriele, and T Kaido, and D Woodrow, and J Moss, and M Ferrantini, and E Proletti, and L Santodonato, and C Rozera, and C Maury, and F Belardelli
Interferon and murine leukemia. II. Factors related to the inhibitory effect of interferon preparations on development of Friend leukemia in mice.
January 1967, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
L Gabriele, and T Kaido, and D Woodrow, and J Moss, and M Ferrantini, and E Proletti, and L Santodonato, and C Rozera, and C Maury, and F Belardelli
Long-term response to interferon-alpha in a patient with systemic mastocytosis and chronic myelomonocytic leukemia.
September 1994, American journal of hematology,
Copied contents to your clipboard!